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Abstract:  The  cytolethal  distending  toxins  (CDTs),  produced  by  a  variety  of  
Gram-negative pathogenic bacteria, are the first bacterial genotoxins described, since they 
cause DNA damage in the target cells. CDT is an A-B2 toxin, where the CdtA and CdtC 
subunits are required to mediate the binding on the surface of the target cells, allowing 
internalization  of  the  active  CdtB  subunit,  which  is  functionally  homologous  to  the 
mammalian  deoxyribonuclease  I.  The  nature  of  the  surface  receptor  is  still  poorly 
characterized, however binding of CDT requires intact lipid rafts, and its internalization 
occurs via dynamin-dependent endocytosis. The toxin is retrograde transported through the 
Golgi  complex  and  the  endoplasmic  reticulum,  and  subsequently  translocated  into  the 
nuclear compartment, where it exerts the toxic activity. Cellular intoxication induces DNA 
damage and activation of the DNA damage responses, which results in arrest of the target 
cells  in  the  G1  and/or  G2  phases  of  the  cell  cycle  and  activation  of  DNA  repair 
mechanisms. Cells that fail to repair the damage will senesce or undergo apoptosis. This 
review will focus on the well-characterized aspects of the CDT biology and discuss the 
questions that still remain unanswered. 
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DNA  damage;  DNA  damage  response;  survival  signals;  virulence  factor;  chancroid; 
periodontitis; colitis/hepatitis 
 




The cytolethal distending toxins (CDTs) comprise a family of bacterial proteins toxins produced by 
a variety of Gram negative bacteria, such as Escherichia coli, Aggregatibacter actinomycetemcomitans, 
Haemophilus ducreyi, Shigella dysenteriae, Campylobacter sp., Helicobacter sp., and Salmonella enterica. 
CDT  and  Colibactin,  a  putative  hybrid  peptide-polyketide  genotoxin  produced  by  commensal  
E. coli strains [1], are the first bacterial genotoxins described, having the unique characteristic to cause 
DNA damage in the target cells. 
In this review, we will focus on the molecular mode of action, the internalization pathway and the 
cellular responses induced by CDT intoxication. We will further discuss the role of these toxins as 
virulence factors in bacterial pathogenesis. 
To facilitate the reading, we have adopted the nomenclature proposed by Thelestam et al., where 
each  CDT  is  specified  by  indicating  the  initials  of  the  producing  bacterium  before  CDT  and,  if 
necessary, the strain number or other common designation after CDT (e.g., HdCDT: H. ducreyi CDT 
or EcCDT-I: E. coli CDT type I) [2]. 
2. CDT Structure and Enzymatic Activity 
CDT is the product of an operon encoding three proteins: CdtA, CdtB and CdtC. All three subunits 
are essential to confer full activity of the holotoxin (reviewed in [3]). 
The crystal structure of the H. ducreyi CDT (HdCDT) has been solved by Nesic and collaborators, 
and revealed that the holotoxin is a tripartite complex. The CdtA and CdtC subunits are lectin-type 
molecules, sharing structural homology with the B-chain repeats of the plant toxin ricin. The CdtB 
subunit adopts the canonical four-layered fold of the DNase I family: a central 12-stranded β-sandwich 
packed between outer α-helices and loops on each side of the sandwich  [4]. The crystal structure 
confirms previous data, demonstrating that CdtB shares five conserved residues with the active site of 
the mammalian DNase I, and possesses DNase capacity in vitro and when ectopically expressed or 
microinjected in eukaryotic cells. Mutation in any conserved residue important for the catalytic activity 
or the Mg
2+ binding abolishes the ability of CdtB to cleave DNA in vitro and to induce DNA damage 
responses in vivo [5–8]. 
The  three  subunits  form  a  complex  with  three  globular  protein-protein  interfaces  (CdtA-CdtB,  
CdtA-CdtC and CdtB-CdtC). Furthermore, the CdtA and CdtC subunits present non-globular amino 
acid extensions at the amino- and carboxyl-termini, which interact with each other and with the CdtB 
subunit. Two very conserved structures can be observed within the surface formed by the CdtA and 
CdtC subunits: (1) a large aromatic cluster of eight bulky side-chains in CdtA; (2) a deep groove 
formed by the juxtaposition of these subunits. Mutations of the aromatic patch do not change the 
stability of the ternary complex, but completely abolished the ability of the toxin to cause cell cycle 
arrest in the human cell line HeLa, suggesting that it plays a relevant role in modulating toxin binding 
to its receptor [4]. 
The  CdtB  subunit  is  the  most  conserved  component  of  the  holotoxin  amongst  all  the  
CDT-producing bacteria. The overall sequence identities of CdtA and CdtC homologs are generally 
less than 30%. However modeling studies based on the HdCDT crystal structure showed that a number 
of structural features are remarkably conserved, such as the close interplay of the CdtA and CdtC Toxins 2011, 3                      
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subunits in the formation of the groove and aromatic patch, and the similarity in their positioning with 
the two lectin repeats in the ricin B-chain. This suggests that these two components of CDT work 
together to mediate cell surface binding and internalization of the holotoxin [9]. 
Based on these data, CDT can be regarded as an A-B2 toxin, where CdtA and CdtC are required for 
binding the holotoxin to the plasma membrane of the target cells, allowing entry of the active CdtB, 
which can translocate to the nucleus and induce DNA lesions. 
There are still several open questions regarding the interaction of the holotoxin with the target cells. 
Little information is available on the biogenesis
 of CDT holotoxin. Furthermore, it is still not clear how 
CdtA and CdtC contribute to the binding on the plasma membrane, and the nature of the CDT receptor still  
remains unknown. 
To  study  the  biogenesis  of  A.  actinomycetemcomitans  (AaCDT),  Ueno  and  co-workers  have  
used an E. coli strain carrying the A. actinomycetemcomitans cdtABC genes. They have shown that  
membrane-associated
 CdtA is a lipoprotein. In the periplasm, CDT is a complex composed
 of CdtA, 
CdtB, and CdtC, whereas CDT in the culture supernatant
 contains an N-terminally truncated CdtA. 
This  suggests  that  CdtA  undergoes  lipid  modification
  during  the  export  process  and  subsequent  
N-terminal processing
 after forming a complex with CdtB and CdtC in the periplasm [10]. 
Using enzyme-linked immunosorbent assays or FACS analysis it was shown that the
 CdtA and 
CdtC subunit from the Campylobacter jejuni (CjCDT), E. coli (EcCDT-II), and AaCDT bind with 
specificity to the surface of the human cell lines HeLa [11,12] or U937 [13], whereas CdtB does not. 
Conversely, Di Rienzo and colleagues showed that the A. actinomycetemcomitans CdtA, but not the 
CdtC subunit, binds to the surface of Chinese hamster ovary (CHO) cells [14]. This discrepancy could 
be related to the different profile of surface molecules expressed on the cell types used. Alternatively, 
it is possible that the CdtA subunit is responsible to bind on the surface of the plasma cell, while CdtC 
may assist the trafficking of the CdtB subunit toward the nuclear compartment, as demonstrated for the 
AaCDT [15]. This hypothesis is supported by the fact that the CdtC, but not the CdtA subunit, transits 
via the Golgi complex similarly to the active CdtB component of the holotoxin [16]. 
What  is  the  nature  of  the  CDT  receptor?  Several  studies  has  been  conducted,  and  yielded  to 
contrasting results. 
EcCdtA-II and CjCdtA are able to compete with the binding of the corresponding CdtC subunits, 
indicating that they interact with the same structure on the target cell, which was identified as N-linked 
glycoproteins [12].  Moreover,  EcCDT  binds  fucose  in  vitro,  and  fucose-specific  lectins  block  
Ec-CDT-mediated cell cycle arrest, presumably by preventing binding of toxin to its receptor. These 
findings suggested that fucose is a binding determinant for Ec-CDT. 
Another study indicated that, similarly to other bacterial proteins toxins, the CDT holotoxin binds to 
surface  glycosphingolipids.  Inhibitors  of  glycosphingolipids  synthesis  prevents  intoxication  of  the 
human monocytic U937 cell line by AaCDT, and thin layer chromatography demonstrates a strong 
binding of the CdtA with
 GM1, GM2, GM3, and Gb4, while CdtC reacts strongly with GM1
 and GM2. 
Intoxication of the U937 cell line is blocked by preincubation of toxin with liposomes that contain 
GM3 [13]. 
Using laser confocal microscopy Shenker et al., have demonstrated that the AaCDT colocalizes with 
GM1-enriched  membrane  regions  of  the  plasma  membrane,  which  are  characteristic  of  membrane  Toxins 2011, 3                      
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rafts  [8,17].  Cholesterol  depletion  by  methyl  β-cyclodextrin  reduces  the  ability  of  the  AaCDT  or 
HdCDT to associate with Jurkat or HeLa cell lines, respectively, and prevents the toxic activity [8,17]. 
Site directed mutagenesis of a human cell line haploid for all chromosomes except chromosome 8 
identified  SGMS1  and  TMEM181  mutants  as  resistant  to  EcCDT.  The  SGMS1  mutation  reduces 
levels of sphingomyelin, a key component of lipid rafts, confirming the previous data obtained for 
HdCDT  and  AaCDT.  TMEM181  is  present  at  the  cell  surface.  Flag-tagged  CDT  is  able  to  bind  
HA-tagged TMEM181, suggesting that this protein may be the EcCDT receptor, however it could not 
be ruled out that TMEM181 plays a role in the trafficking of the receptor-toxin complex [18]. 
The divergent results on factors that mediate the toxin binding on the cell surface may depend on the 
different receptor specificity exhibited by each CDT. It is noteworthy that several CDT are species 
specific:  HdCDT  and  AaCDT  cannot  intoxicate  cells  of  rodent  origin.  Furthermore,  Eshraghi  and  
co-workers have demonstrated that CDTs from H. ducreyi, A. actinomycetemcomitans, E. coli, and  
C. jejuni differ in their abilities to intoxicate host cells. Binding of Aa, Hd, and EcCDT-III, but not 
CjCDT is dependent on the presence of cholesterol. Surprisingly, mutant CHO cells that lack N-linked 
complex  and  hybrid  carbohydrates,  cells  that  lack  glycosphingolipids  or  are  deficient  in  fucose 
biosynthesis are similarly sensitive as the wild type to intoxication by all four CDTs tested, indicating 
that N- and O-glycan, or fucosylated structures are dispensable to mediate toxin binding [19]. 
An exception to the general structure of the CDT holotoxin is the CDT produced by S. enterica, 
serovar Typhi CT18. The cdtB gene is located within a region of the chromosome, however there are no 
homologues of the cdtA or cdtC genes [20]. Ectopic expression of the StCdtB in Cos-2 is sufficient to 
cause  DNA  damage,  and  mutation  of  the  key  conserved  residues  of  the  DNase  activity  abrogates 
toxicity, indicating that this protein acts as a CDT active subunit [21]. CDT intoxication in S. typhi 
infected  cells  requires  the  products  of  two  genes,  named  pltB  (persussis-like  toxin  B)  and  pltA  
(persussis-like toxin A), and similarly to cdtB, their expression is induced after bacteria uptake by the 
host cells. The role of these components is most likely to transport CdtB from its site of production to the 
extracellular medium, from where StCDT can also intoxicate cells that have not been infected with the 
bacterium, in a paracrine manner [22]. 
3. Internalization 
CDT is the first bacterial protein toxin known to act in the nucleus of the target cell. As discussed in 
the previous paragraph, binding to the plasma membrane is a pre-requisite for the intoxication, and as 
many other bacterial protein toxins, CDT has to cross the plasma membrane to reach the nucleus. The 
internalization pathway has been mainly studied using HdCDT, AaCDT and EcCDT-II as a model. 
HdCDT is internalized in HeLa cells by dynamin-dependent endocytosis [23], but it does not require 
clathrin,  since  conditional  knock  down  of  this  protein  by  RNA  interference  does  not  prevent  
intoxication [16]. Induction of CDT-mediated DNA damage is completely inhibited under conditions 
that block the fusion of the endosomal compartment with downstream compartments, indicating that 
the toxin further transits through the endosomal compartment [23]. Using a holotoxin with a modified 
CdtB  subunit,  carrying  either  a  sulfation  site,  or  a  sulfation  and  three  partially  overlapping 
N-linked glycosylation sites at the C-terminus, it was possible to demonstrate that the active subunit 
transits  via  the  trans-Golgi,  where  sulfation  occurs,  and  it  is  retrograde  translocated  via  the 
endoplasmic reticulum (ER), where it is glycosylated [8]. Many ER-translocating toxins exploit the Toxins 2011, 3                      
 
176 
ER-associated degradation (ERAD) pathway to transit from the ER to the cytosol. However, CDT 
intoxication occurs in cells carrying an altered ERAD system, and its translocation does not require 
protein unfolding [8,24]. Furthermore, using a combination of confocal microscopy analysis with ER 
specific markers and biochemical assays, Guerra et al. have failed to detect the presence of the CdtB 
subunit in the cytosol of the intoxicated cells. All these data indicate that most likely the active subunit 
of CDT is directly translocated from the ER to the nucleus, where it exerts its genotoxic activity [24]. 
Figure 1 summarizes the key steps in CDT internalization. 
Figure 1. Cytolethal distending toxin (CDT) internalization pathway. Binding of CDT is 
dependent  on  the  presence  of  intact  lipid  rafts,  and  the  toxin  is  internalized  via  
dynamin-dependent endocytosis into early and late endosomes. The CdtB subunit further 
transits  to  the  Golgi  complex,  and  is  then  retrogradely  transported  to  the  endoplasmic 
reticulum (ER). Translocation from the ER does not require the ER-associated degradation 
(ERAD) pathway, and protein unfolding. 
 
How the nuclear translocation of the CdtB subunit takes place is still an open question. Nishikubo 
and co-workers have identified an atypical nuclear localization signal (NLS) within the amino-terminal 
region  of  the  AaCdtB,  which  is  essential  for  nuclear  translocation  of  the  recombinant  His-tagged 
CdtB-GFP. Deletion of 11 amino acids within the NLS sequence of CdtB abolishes intoxication [25]. 
On the other hand, two NLS sequences, designated as NLS1 and NLS2, have been identified in the 
carboxy-terminal region of the EcCdtB-II. Deletion of these two regions prevents induction of cell 
cycle arrest and nuclear localization of the holotoxin, without affecting its DNase activity, as tested in 
in  vitro  assays  [26].  Interestingly,  deletion  of  each  of  these  sequences  produces  a  differential Toxins 2011, 3                      
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localization  of  the  active  toxin  subunit.  Cells  intoxicated  with  a  holotoxin  containing  the  
EcCdtB-II-NLS1 display a perinuclear distribution, which is consistent with trapping of the active 
toxin component in  the late endosome and/or ER  compartment.  A diffuse cytoplasmic staining is 
observed in cells exposed to the EcCdtB-II-NLS2 containing toxin. It is possible that this second 
NLS may  act  as  scavenger motif to  retrieve CdtB molecules, which have escaped to  the cytosol, 
similar to the suggested ER retention function of the KDEL sequence in cholera toxin [27]. 
The presence of NLSs in entirely different parts of the CdtB molecule in the AaCdtB and EcCdtB-II is 
still  puzzling,  considering  the  high  degree  of  conservation  of  this  subunit  amongst  different  bacteria  
species [28]. 
Another important point of discussion is the observation that the majority of the studies on CDT 
internalization have been performed using recombinant purified soluble holotoxin. However, it has 
been  reported  that  both  EcCDT-II  and  CjCDT  are  secreted  within  outer  membrane  vesicles  
(OMVs) [29,30]. It will be interesting to assess whether the delivery of the OMV-associated holotoxin 
follows the same route as the soluble complex. 
4. Cellular Responses 
4.1. Induction of DNA Damage 
The  first  demonstration  that  CDT  is  a  genotoxin  stems  from  the  work  of  Elwell  et  al.  and  
Lara-Tejero  et  al.  who  identified  position-specific  homology  between  the  CdtB  subunit  from  
EcCDT-II  and  CjCDT,  respectively,  and  the  mammalian  DNase  I.  The  sequence  conservation  is 
associated with a functional homology, since preparation of EcCDT-II completely degrades a DNA 
plasmid substrate in 12 h, and ectopic expression of CjCdtB induces  nuclear  fragmentation and a 
marked chromatin disruption in HeLa cells [5,6]. Mutations of the conserved residues required for 
catalysis or for magnesium binding abolish both the DNase activity as well as the cytotoxic effect. 
Direct demonstration of CDT-induced DNA fragmentation was subsequently shown using pulsed 
field gel electrophoresis (PFGE) analysis both in mammalian cells intoxicated with HdCDT and in 
budding yeast carrying a conditional CjCdtB expressing plasmid [7,31]. 
It is noteworthy that the efficiency of CDT to degrade DNA is much lower than that of purified  
bovine DNase I, as seen both in in vitro assays with EcCDT-II and upon microinjection of HdCDT in  
HeLa cells [32,33]. 
4.2. Activation of DNA Damage Responses 
To protect the genome from DNA damage induced by endogenous or exogenous sources, cells 
activate a series of complex mechanisms. These mechanisms are referred to as DNA damage responses 
(DDRs) that act to repair the genome and minimize the probability of lethal or permanent genetic 
damage.  The  cellular  response  to  DNA  damage  encompasses  multiple  repair  mechanisms  and 
checkpoint  responses  that  can  delay  cell  cycle  progression  or  modulate  DNA  replication,  and  are 
coordinated  primarily  by  two  distinct  kinase  signaling  cascades:  the  ATM-Chk2  and  ATR-Chk1 
pathways. The ATM-Chk2 and ATR-Chk1 pathways respond to different types of DNA damage: ATM 
is recruited to and activated primarily at DNA double-strand breaks (DSBs) in conjunction with the Toxins 2011, 3                      
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MRE11:RAD50:NBS1 (MRN) sensor  complex, while ATR is  recruited  at  sites of single-stranded 
DNA  (ssDNA)  in  association  with  its  partner  protein,  ATRIP.  Recent  evidence  indicates  that  the 
ATR–Chk1 repair axis is also activated in an ATM-dependent manner in response to DSBs. Prolonged 
exposure to DNA damage will chronically activate the DDR machinery, including the ATM-Chk2-p53 
axis, resulting in either cell death or a long-term cell cycle arrest state known as cellular senescence 
(reviewed  in  [34]).  This  response  represents  an  inducible  barrier  against  acquisition  of  genomic 
instability and tumor initiation and/or progression (reviewed in [35]). 
Based on the DNase activity of CDT, it is not surprising that intoxicated cells activate the full 
pattern of DDRs. The cells exposed to CDTs have been shown to arrest in the G1 and/or G2 phases of 
the cell cycle, or undergo apoptosis, depending on the cell type [36–39]. The CDT-induced cell cycle 
arrest resembles the checkpoint response to ionizing radiation (IR), characterized by activation of the 
ATM kinase and ATM-dependent induction of the tumor suppressor p53 and its transcriptional target, 
the cyclin-dependent kinase inhibitor p21, phosphorylation of histone H2AX and re-localization of the 
DNA repair proteins, such as MRE11 and RAD50, to the sites of DNA DSBs [33,39–42]. 
Guerra  et  al.  recently  demonstrated  that  the  proto-oncogene  MYC  plays  an  important  role  in 
response to CDT- and IR-induced DNA damage, since MYC is required for prompt activation of the  
ATM-dependent DNA damage pathway in irradiated or intoxicated cells [43]. 
Normal  and  cancer  cells  that  survive  the  acute  phase  of  intoxication  by  HdCDT  possess  the 
hallmarks of cellular senescence. This characteristic phenotype includes persistently activated DNA 
damage  signaling  (detected  as  53BP1/γH2AX-positive  foci),  enhanced  senescence-associated  
β-galactosidase activity, expansion of PML nuclear compartments, and expression of IL-6, IL-8, IL-20 
and IL-24 [44]. 
A genome wide analysis performed in budding yeast has identified homologous recombination (HR), 
activation of the DNA damage checkpoint, and S-phase
 checkpoint as essential mechanisms for the 
response  to
  CdtB.  This  study  could  not  conclusively  demonstrate  a  contribution  of  the  non  
homologous-end
 joining (NHEJ) repair pathway to the CdtB-induced DNA lesion. Interestingly, the 
genes identified in this analysis indicate
 that there are specific features of the CdtB response that do not
 
fully overlap with the components required for direct DSBs [45]. Conversely, as reviewed above, the 
majority of the responses activated in mammalian cells fully support a relevant role of the ATM-Chk2 
axis in response to CDT-induced DNA damage. 
4.3. Survival Signals Activated in Intoxicated Cells 
The  survival  of  cells  with  damaged  DNA  may  promote  genomic  instability  and  favor  tumor 
initiation and/or progression (reviewed in [46,47]). Characterization of the survival signals in response 
to CDT intoxication is therefore relevant to understand whether infection with CDT-producing bacteria 
can contribute to genomic instability and therefore tumor progression. 
In  adherent  cells,  irradiation  or  CDT  intoxication  is  associated  with  formation  of  actin  stress  
fibers [48,49]. This effect is regulated by the activation of the small GTPase RhoA, and promotes cell 
survival in intoxicated cells [31]. Activation of RhoA and actin stress fiber formation in response to 
CDT is dependent on the RhoA-specific guanine nucleotide exchange factor (GEF) Net1, which is 
dephosphorylated at a critical inhibitory site [50]. Toxins 2011, 3                      
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The DNA damage-dependent Net1/RhoA signaling diverges into two different effector cascades: 
one dependent on the RhoA kinases ROCKI and ROCKII, which controls the formation of actin stress 
fibers; and one regulated by the mitogen-activated protein kinase (MAPK) p38 and its downstream 
target MAPK-activated protein kinase 2, which promotes cell survival [50]. 
The characteristic cell distension observed in intoxicated cells of epithelial and mesenchymal origin 
is RhoA-independent, and requires a functional PI3-kinase and its downstream effector mTOR [31]. 
The cellular responses to CDT are summarized in Figure 2. 
Figure  2.  CDT-induced cellular  responses. The protein kinase  ATM is  activated upon  
CDT-induced  DNA  damage.  c-MYC  is  required  for  proper  activation  of  the  
ATM-dependent  DNA  damage  response, which in  turn recruits  phosphorylated  histone 
H2AX and the DNA repair proteins, such as the MRN complex, at the sites of DNA strand 
break. As consequence of the DNA damage checkpoint responses, cells are arrested in the 
different phases of the cell cycle, and in case of failure to properly repair the DNA damage, 
they senesce or die by apoptosis. CDT-induced DNA damage promotes dephosphorylation 
of  Net1,  and  consequent  activation  of  RhoA,  which  regulates  two  distinct  pathways:  
(1) induction of actin stress fibers, which requires the RhoA kinases ROCKI and ROCKII; 
(2)  activation  of  p38  MAPK,  associated  with  a  delayed  cell  death.  The  characteristic 
distension observed in epithelial cells is dependent on activation of the PI3-kinase (PI3K) 
and its downstream effector mTOR. 
 
To identify novel CDT-induced survival signals, we have screened a yeast deletion library in cells 
expressing the CdtB active subunit under the control of a galactose-inducible promoter. This screen 
identified  78  deletion  mutants  with  reduced  growth  rate  following  inducible  expression  of  CdtB. 
Bioinformatics analysis revealed that 12 human orthologs  of these genes  interacts  with  the RhoA 
signaling pathway. Functional studies in mammalian cells showed that FEN1 (yeast ortholog RAD27) Toxins 2011, 3                      
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promotes RhoA activation, MAPK p38 phosphorylation and ultimately cell survival in response to 
CDT intoxication [51]. 
4.4. CDT-Induced Apoptosis 
While the majority of cells of epithelial and mesenchymal origin are arrested in different phases of 
the cell cycle, and cell death is a very late event observed after more than 96 h post-intoxication, B and 
T lymphocytes exposed to HdCDT or AaCDT, respectively, are more susceptible to apoptosis [39,52]. 
Most  of  the  studies  aimed  at  understanding  the  molecular  mechanisms  associated  with  
CDT-induced cell death have been performed using as model AaCDT. 
Treatment of activated human T cells with AaCDT induces activation of caspases 8, 9 and 3, and 
DNA fragmentation is detectable 72–96 h after intoxication [52]. These effects are associated with 
mitochondrial  changes,  such  as  decreased  transmembrane  potential  and  elevated  levels  of  reactive 
oxygen species. Overexpression of Bcl-2 decreases the CDT-induced apoptosis, without inhibiting the 
G2 arrest [52]. AaCDT intoxication also induces cell death in a biphasic manner in two T cell
 leukemia 
cell lines, Jurkat and MOLT-4 [53]. In the presence of the caspase inhibitor z-VAD-fmk, CDT-induced
 
apoptosis is completely blocked for 16 h in Jurkat cells, suggesting
 that CDT-induced cell death is 
dependent on caspase activation. However, a subpopulation of cells dies at a later stage of intoxication 
(more than 24 h post-intoxication) by a caspase-independent
 cell death [54]. 
Also cells of the myeloid linage are sensitive to CDT mediated cell death. AaCDT intoxication 
induces apoptosis
 in both proliferating and non-proliferating U937 monocytic cells. The induction of 
apoptosis in proliferating U937 cells is caspase-dependent and requires
 the DNase activity of CdtB. In 
contrast,  apoptosis  in  non-proliferating
 cells  is  caspase  independent  [55].  Immature  dendritic  cells 
exposed to HdCDT show signs of cell death 24 h to 48 h after intoxication [33]. Interestingly the effect 
of HdCDT on DCs is dependent on their stage of differentiation, since LPS-treated DCs are resistant to 
HdCDT-induced cell death  [33]. It  is  possible that  upon DC  maturation, the repertoire of surface 
molecules is modified in such a way that HdCDT is no longer able to bind and be internalized. This 
hypothesis  is  supported  by  the  lack  of  activation  of  DNA  damage  sensor  complex  MRN  and 
stabilization of p53 in LPS-treated DCs exposed to HdCDT [33]. 
4.5. CDT as Phosphatase 
Shenker  and  colleagues  have  reported  that  the  CdtB  subunit  from  A.  actinomycetemcomitans 
exhibits PI-3,4,5-triphosphate (PI-3,4,5-P3) phosphatase activity similar to that of the tumor suppressor 
phosphatases PTEN and SHIP1. Mutation analysis indicates that CDT toxicity correlates with the 
phosphatase  activity,  and  lymphocytes  treated  with  the  toxin  exhibit  reduced  PI-3,4,5-P3  levels. 
Finally,  lymphocyte  sensitivity  to  CDT-induced  G2  arrest  correlates  with  intracellular  levels  of  
PI-3,4,5-P3 [56]. 
Conversely, specific CdtB mutations  that inhibit  the phosphatase activity but  retain the DNase 
activity, are sufficient to induce cell death in proliferating U937 monocytes [55]. Furthermore, the G2 
arrest and cell death induced by conditional expression of CdtB in Saccharomyces cerevisiae depend 
exclusively on its DNase-catalytic residue, since yeast does  not harbor the substrate for the CdtB Toxins 2011, 3                      
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phosphatidylinositol-3,4,5-triphosphate  phosphatase  activity.  These  results  suggest  that  the  DNA 
damaging activity alone is sufficient to confer the CdtB toxicity [57]. 
The discrepancy between the requirements of the different enzymatic activities of CDT may depend 
on the cell type used as model. It is conceivable that T lymphocytes are more susceptible than all the 
other cell lines tested to the phosphatase activity of CDT. 
5. Role of CDT as Virulence Factor 
In this paragraph, we will briefly review the possible role of CDT in bacterial pathogenesis, and we 
will  focus  on  three  bacterial-associated  diseases:  inflammatory  bowel  disease  and  CDT-producing 
enteric bacteria; periodontitis and A. actinomicetemcomitans; delayed wound healing in chancroid and 
H. ducreyi (Figure 3). 
Figure 3. Schematic representation of the possible role of CDT in the pathogenesis of three 
bacterial diseases: chancroid (H. ducreyi), periodontitis (A. actinomicetemcomitans), and 
chronic colitis or hepatitis (Campylobacter and Helicobacter sp). 
 
5.1. Role of CDT in Colitis and Inflammation-Associated Carcinogenesis 
Several  CDT-producing  bacteria  are  associated  with  gastro-enteritis,  including  C.  jejuni  and 
Helicobacter hepaticus. 
In  the  past  ten  years,  it  has  been  clearly  shown  that  chronic  inflammation  is  associated  with 
enhanced  risk  of  tumor  development,  and  the  best-studied  model  is  colorectal  carcinoma  
(CRC)  [58,59].  It  is  likely  that  in  the  case  of  bacterial  infection  several  events,  such  as  the 
establishment of persistent inflammation, the production of toxins that interfere with regulation of cell Toxins 2011, 3                      
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cycle progression and apoptosis in association with host genetic factors contribute to the acquisition of 
genomic instability, and consequently tumor initiation and/or progression.  
Epidemiological  evidence  has  linked  chronic  bacterial  infections  with  increased  risk  of  tumor 
development. Helicobacter pylori is associated with gastric cancers and has been classified as a type I 
carcinogen  by  the  World  Health  Organization  [60].  There
 is  growing  evidence  that  other  gastric 
Helicobacter  species  may  be  associated  with  chronic
 liver  diseases  in  humans,  including  chronic 
hepatitis, liver
 carcinoma, chronic cholecystitis, and cholangiocarcinoma [61,62]. 
To study the role of CDT in chronic infection and inflammation, several animal models have been 
developed.  Adult  severe  combined  immunodeficient
  (SCID)  mice  are  susceptible  to  infection  by 
Campylobacter sp. To test the role of CDT in the establishment of persistent infection, these mice were 
infected by intragastric inoculation either with the wild type strain CJ81-176, or with an isogenic strain 
harboring an inactivating insertion within the cdtB gene (Cj81-176 mutant cdtB). Blood, liver and 
spleen samples were taken 2 h, 6 h and 24 h post-infection (p.i.) to assess for the presence of invasive 
bacteria.  More  bacteria-positive  samples  were  detected  in  mice  infected  with  the  wild  type  CDT 
producing strain compared to the CdtB deficient  C. jejuni, indicating that CDT promotes bacteria 
invasion [63]. However, this was not associated with enhanced levels of intestinal colonization by  
7 days p.i. in mice infected with the wild type or the mutant strains [63]. 
Conversely, gastric colonization of mucin deficient 129/SvJ mice by C. jejuni was enhanced if the 
bacteria produced a functional CDT [64], and C. jejuni carrying a wild type CDT were able to colonize 
the gastro-intestinal tract in 50% of C57BL/129 mice 4 months p.i., while an isogenic strain deficient 
for  CDT  expression  was  not  detected  in  any  of  the  infected  mice  [65].  Bacterial  clearance  was 
dependent  on  a  functional  NF-κB  complex,  since  mice  homozygously  deficient  for  p50  and 
heterozygous  for  p65  (p50
−/−  p65
+/−),  referred  to  as  3×   mice,  showed  persistent  colonization  of 
stomachs and lower bowels with both C. jejuni strains at 2 and 4 months p.i. [65]. 3×  mice colonized 
with the cdtB mutant strain had significantly less gastritis and hyperplasia at 4 months post-infection 
than  3×   mice  colonized  with  wild-type  C.  jejuni,  indicating  that  CDT  promotes  proinflammatory 
responses [65]. In line with this hypothesis, Hickey and colleagues demonstrated that CjCDT elicits 
secretion  of  IL-8,  an  important  mediator  of  inflammation  in  INT407  (human  embryo  intestinal 
epithelial) cells [66]. 
CDT is also produced by H. hepaticus, an enteropathogenic species, which naturally infects the 
distal  gastrointestinal  tract  of  mice  [67].  HhCDT  was  shown  to  play  a  crucial  role  in  persistent 
bacterial colonization of the small intestine of Swiss Webster mice [68], which was associated with 
significantly
 higher production of Th1-associated immunoglobulin G2a (IgG2a), Th2-associated
 IgG1 
and mucosal IgA in the mice infected with wild type H. hepaticus when compared
 to animals exposed 
to the isogenic strain HhcdtBm7, where the cdtB gene was inactivated by transposon mutagenesis [68]. 
Challenge of
 C57BL/6 interleukin 10
 deficient mice with isogenic H.
 hepaticus mutants revealed that 
CDT  expression  is  not  required
  for  colonization  of  the  murine  gut.  However,  a  CDT-negative  
H. hepaticus mutant had a significantly diminished capacity
 to induce lesions in this murine model of 
inflammatory bowel
 disease [69]. 
Infection of A/JCr mice with wild type or an isogenic mutant of H. hepaticus lacking CDT activity 
induced comparable levels and severity of chronic hepatitis at both 4 and 10 months p.i. The presence 
of CDT  was  instead necessary  for the development of hepatic dysplasic nodules 10 months  after Toxins 2011, 3                      
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infection. This effect was associated with enhanced hepatic transcription of proinflammatory (TNF-α, 
IFN-γ  and  Cox-2,  IL-6  and  TGF-α)  and  anti-apoptotic  (Bcl-2  and  Bcl-XL)  genes,  upregulation  of 
hepatic mRNA levels of components of the NF-κB pathway (p65 and p50), and increased hepatocyte 
proliferation compared with the control or the CDT mutant-infected mice [70]. 
Collectively, these data demonstrate that CDT is an important virulence factor to promote invasion 
of  enteric  bacteria  and  activate  proinflammatory  responses  that  can  be  associated  with  chronic 
inflammation, and its possible progression toward malignant transformation. 
5.2. Chancroid and Wound Healing 
H. ducreyi is the causative agent of chancroid, a sexually transmitted disease, characterized by soft 
and slowly healing genital ulcers (reviewed in [71]).  
Cutaneous wound healing is a complex process involving blood clotting, inflammation, new tissue 
formation,  and  tissue  remodeling.  Neutrophils  normally  begin  arriving  at  the  wound  site  within 
minutes  of  injury,  to  control  bacterial  infection  and  produce  proinflammatory  cytokines,  which 
probably  serve  as  some  of  the  earliest  signals  to  activate  local  fibroblasts  and  keratinocytes. 
Neutrophils recruitment is followed by accumulation of macrophages, which are essential for effective 
wound  healing,  since  healing  is  severely  impaired  if  macrophage  infiltration  is  prevented.  
Re-epithelialization  of  the  skin  requires  both  migration  and  rapid  proliferation  of  keratinocytes, 
fibroblasts and epithelial cells (reviewed in [72]). Adaptive immunity, specifically T lymphocytes are 
essential for a normal wound healing outcome (reviewed in [73]). 
Involvement  of  CDT  in  ulcer  formation  was  showed  in  a  rabbit  model  of  chancroid,  where 
intradermal inoculation of H. ducreyi co-administered with purified HdCDT resulted in significant 
aggravation of the bacteria-induced inflammatory lesions and in ulcer development [74]. 
How can CDT contribute to the delayed would healing observed in chancroid? It has been shown 
that HdCDT affects cell proliferation and survival of many cell types involved in wound healing, such 
as primary human fibroblasts, primary keratinocytes and cells of epithelial origin [39,75]. Furthermore, 
HdCDT may interfere with angiogenesis, since it inhibits proliferation of normal human microvascular 
endothelial cells from adult dermal tissue (HMVEC-d) and human umbilical vein endothelial cells 
(HUVEC), preventing new blood vessel formation in an in vitro angiogenesis model [76].  
HdCDT affects also effector cells of the innate and adaptive immune system: intoxication inhibits 
proliferation  and  IFN-γ  secretion  of  T  lymphocytes  and  induces  apoptosis  of  B  
lymphocytes  [39,48,77],  and  monocyte-derived  DCs,  the  key  activators  of  the  adaptive  immune 
responses  [33,78].  Upon  phagocytosis  of  heat-inactivated  H.  ducreyi,  DCs  produces  the 
proinflammatory cytokines, IL-1β, IL-6, IL-8, and TNF-α. Preincubation of DCs with purified HdCDT 
results in an approximate 50% reduction in cytokine secretion [78], suggesting an immuno-inhibitory 
effect of the toxin. 
Targeting  DCs  may  represent  a  strategy  to  avoid/delay  the  onset  of  immune  responses,  while 
inhibition of cellular proliferation may impair the wound healing process, thus increasing pathogen 
spread from host to host and/or favoring the establishment of a life-long latent infection. Toxins 2011, 3                      
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5.3. Periodontitis and A. actinomycetemcomitans 
Periodontitis is a chronic inflammatory disease associated with loss of the supporting connective 
tissue and alveolar bone around teeth. A. actinomycetemcomitans has been described as a member of 
the indigenous oral microbiota of humans [79]. 
Does  AaCDT  contribute  to  periodontitis?  The  lack  of  suitable  animal  models  does  not  allow 
answering  this  question  directly.  However,  AaCDT  may  interfere  with  the  normal  periodontal 
connective tissue remodeling equilibrium, by over-stimulating osteoclast-dependent bone resorption. 
Production of mature osteoclasts is regulated by interaction between the receptor activator of NF-κB 
ligand (RANKL) present on the surface of hematopoietic bone marrow stromal cells, periosteal tissue 
osteoblasts, as well as T lymphocytes, and its receptor (RANK) expressed on osteclast progenitor cells. 
This process is negatively regulated by Osteoprotegerin (OPG), which acts as a decoy receptor for 
RANKL,  preventing  its  interaction  with  RANK  and  osteoclast  maturation  (reviewed  in  [80]). 
Therefore, the ratio of RANKL/OPG expression determines the amount of osteoclasts formed and 
controls the degree of bone resorption. It has been shown that AaCDT is sufficient to induce RANKL 
expression and downregulate OPG mRNA expression in gingival fibroblasts (GF) and periodontal 
ligament  cells  (PDLC),  obtained  from  healthy  individuals,  and  in  the  T  lymphocyte  cell  line  
Jurkat [81,82]. 
Furthermore, AaCDT blocks proliferation and causes apoptosis of mitogen activated human CD8
+ 
and CD4
+ T lymphocytes [37,52–54], and peripheral blood mononuclear cells (PBMC) exposed to 
AaCDT are able to produce a wide range of pro-inflammatory cytokines, such as IL-1β, IL-6, IL-8, 
and IFN-γ, while no secretion of IL-10, IL-12 and TNF-α was detected [83]. It is conceivable that 
AaCDT  stimulates  the  innate  host  immune  response,  promoting  production  of  a  specific  set  of 
cytokines, leading to an inflammatory pathology, inhibiting T cell functions and possibly creating a 
suitable niche for bacterial survival and proliferation. 
6. Conclusions 
In spite of the exponential progress in understanding the CDT mode of action and the cellular 
responses induced by intoxication, there are still many questions that need to be answered regarding 
the biology of CDT and its role in disease. We still do not know: (1) how the toxin is translocated from 
the ER to the nucleus where it exerts its genotoxic activity, and which cellular partners regulate the 
intracellular trafficking of the toxin; (2) why evolution has positively selected a bacterial genotoxin;  
(3) what is the contribution of CDT in promoting genomic instability in chronic infections. We are 
looking  forward  to  an  even  more  exciting  and  productive  period  of  research  in  the  field  of  the 
cytolethal distending toxins. 
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